Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy
- 341 Downloads
RNA interference (RNAi) has potential to be a novel therapeutic strategy in diverse areas of medicine. In this paper, we report on targeted RNAi for the treatment of a viral cardiomyopathy, which is a major cause of sudden cardiac death or terminal heart failure in children and young adults. RNAi therapy employs small regulatory RNAs to achieve its effect, but in vivo use of synthetic small interfering RNAs is limited by instability in plasma and low transfer into target cells. We instead evaluated an RNAi strategy using short hairpin RNA (shRdRp) directed at the RNA polymerase (RdRP) of coxsackievirus B3 (CoxB3) in HeLa cells, primary rat cardiomyocytes (PNCMs) and CoxB3-infected mice in vivo. A conventional AAV2 vector expressing shRdRp protected HeLa against virus-induced death, but this vector type was unable to transduce PNCMs. In contrast, an analogous pseudotyped AAV2.6 vector was protective also in PNCMs and reduced virus replication by >3 log10 steps. Finally, we evaluated the intravenous treatment of mice with an AAV2.9-shRdRp vector because AAV9 carries the most cardiotropic AAV capsid currently known for in vivo use. Mice with CoxB3 cardiomyopathy had disturbed left ventricular (LV) function with impaired parameters of contractility (dP/dt max = 3,006 ± 287 vs. 7,482 ± 487 mmHg/s, p < 0.01) and diastolic relaxation (dP/dt min = −2,224 ± 195 vs. −6,456 ± 356 mmHg/s, p < 0.01 and Tau = 16.2 ± 1.1 vs. 10.7 ± 0.6 ms, p < 0.01) compared to control mice. AAV2.9-shRdRp treatment significantly attenuated the cardiac dysfunction compared to control vector-treated mice on day 10 after CoxB3 infection: dP/dt max = 3,865 ± 354 vs. 3,006 ± 287 mmHg/s (p < 0.05), dP/dt min = −3,245 ± 231 vs. −2,224 ± 195 mmHg/s (p < 0.05) and Tau = 11.9 ± 0.5 vs. 16.2 ± 1.1 ms (p < 0.01). The data show, for the first time, that intravenously injected AAV9 has the potential to target RNAi to the heart and suggest AAV9-shRNA vectors as a novel therapeutic approach for cardiac disorders.
KeywordsVirus infections Coxsackievirus RNA interference Gene silencing Gene therapy
pseudotyped AAV2.6 vector
maximal rate of pressure increase over time
multiplicity of infection
primary neonatal cardiomyocyte
RNA-dependent RNA polymerase
short hairpin RNA
short interfering RNA
isovolumetric relaxation time constant
vector genomes per cell
We thank Dr. J. Kleinschmidt and Dr. J.M. Wilson for kindly providing the AAV packaging plasmids and Denise Werk und Steffen Schubert for the excellent assistance. This work has been supported by the Deutsche Forschungsgemeinschaft through SFB Transregio 19 by project grants C5 to WP and HF, C1 to JK and VAE and Z3 to CT.
Note added in proof
An important recent study of AAV 1–9 tropism after intravenous injecton comprehensively demonstrated that AAV9 is superior to the other serotypes by 1–3 orders of magnitude with respect to both cardiotropism and CMV promotor-driven GFP expression level . Although the current paper employs U6 promoter-driven shRNA transcription instead this new study suggests that currently only AAV9 is suitable to generate therapeutic RNAi levels within the heart.
- 3.Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R (1992) Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 89:314–318PubMedCrossRefGoogle Scholar
- 6.Goodfellow IG, Evans DJ, Blom AM, Kerrigan D, Miners JS, Morgan BP, Spiller OB (2005) Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol 79:12016–12024PubMedCrossRefGoogle Scholar
- 7.Yuan J, Stein DA, Lim T, Qiu D, Coughlin S, Liu Z, Wang Y, Blouch R, Moulton HM, Iversen PL, Yang D (2006) Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol 80:11510–11519PubMedCrossRefGoogle Scholar
- 8.Fechner H, Pinkert S, Wang X, Sipo I, Suckau L, Kurreck J, Dorner A, Sollerbrant K, Zeichhardt H, Grunert HP, Vetter R, Schultheiss HP, Poller W (2007) Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther 14:960–971PubMedCrossRefGoogle Scholar
- 20.Fechner H, Suckau L, Kurreck J, Sipo I, Wang X, Pinkert S, Loschen S, Rekittke J, Weger S, Dekkers D, Vetter R, Erdmann V, Schultheiss H-P, Paul M, Lamers J, Poller W (2007) Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther 14:211–218PubMedCrossRefGoogle Scholar
- 23.Fechner H, Wang X, Srour M, Siemetzki U, Seltmann H, Sutter A, Scherübl H, Zouboulis C, Schwaab R, Hillen W, Schultheiss H-P, Poller W (2003) A novel tetracycline-controlled transactivator–transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther 10:1680–1690PubMedCrossRefGoogle Scholar
- 27.Werk D, Schubert S, Lindig V, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J (2005) Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor. Biol Chem 386:857–863PubMedCrossRefGoogle Scholar
- 28.Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, vanVeghel R, Houtsmuller A, Schultheiss H-P, Lamers J, Poller W (1999) Expression of Coxsackie-adenovirus-receptor and av-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6:1520–1535PubMedCrossRefGoogle Scholar